BMS Archive

Fungi · Scientific monograph

Cordyceps militaris

Orange Caterpillar Fungus

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Stress Response Research, Inflammatory Pathways, Exercise & Physical Performance Research

Research overview

Historical use

Historically used interchangeably with C. sinensis in Traditional Chinese Medicine, though less prized. Growing interest as a cultivatable alternative since wild C. sinensis is prohibitively expensive and endangered. Used in TCM for similar indications: fatigue, sexual dysfunction, respiratory conditions.

Modern research context

Contains higher concentrations of cordycepin than wild C. sinensis and is more accessible for research [3]. A randomised controlled trial demonstrated significant improvements in immune response markers in healthy adults following supplementation [1]. Safety has been assessed in randomised clinical trials with cultured Cordyceps preparations [2]. Immunomodulatory, anti-inflammatory, and anti-tumour activities are supported by both in vitro and in vivo evidence [3][4]. Properties including antidiabetic and renoprotective effects remain under active investigation [5].

Adverse effects

Mild GI symptoms (nausea, diarrhoea). Rare allergic reactions. Potential hypoglycaemia with concurrent antidiabetic use.

Contraindications

Anticoagulant therapy. Autoimmune conditions — theoretical risk of exacerbation. Avoid pre-surgery. Caution with immunosuppressants.

Clinical and phytochemical data

Used part

Fruiting body and mycelium (commercially cultivated)

Primary active compounds

  • Cordycepin (3'-deoxyadenosine — higher concentration than C. sinensis)

  • Adenosine

  • Polysaccharides

  • Carotenoids (cordyxanthin)

  • Ergosterol

  • Militarinones

Mechanism of action

Cordycepin is the primary bioactive; inhibits mRNA polyadenylation, reducing expression of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β). Activates AMPK pathway, enhancing mitochondrial biogenesis. Immunomodulation via NK cell and macrophage activation. Anti-tumour activity via cell cycle arrest at G2/M phase and apoptosis induction.

Pharmacokinetics

Absorption

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Cordycepin is rapidly deaminated by adenosine deaminase after oral administration; concurrent administration of adenosine deaminase inhibitors (e.g., pentostatin) dramatically increases bioavailability. Human PK studies are limited.

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Cordycepin distributes broadly via equilibrative nucleoside transporters (ENTs) to muscle, liver, and kidney. In animal models, intact cordycepin has been detected in tumour tissue. Rapid plasma deamination limits systemic exposure of the intact molecule. No quantitative human tissue distribution studies are available.

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Metabolic pathway data for cordycepin (primary active compound) available in Lee JB et al. (2019), Sci Rep (PMID 31673018): cordycepin is rapidly deaminated to 3'-deoxyinosine by adenosine deaminase; a nucleoside rescue pathway enables oral bioactivity despite this first-pass degradation. Adenosine deaminase-mediated deamination is the primary metabolic step; subsequent hepatic purine catabolism.

Excretion

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Renal excretion of polar metabolites.

Safety and interactions

Drug interactions

Lack of clinical studies prevents interaction grading. Unknown safety profile with concomitant drug use.

Toxicity

LD50 >3 g/kg (oral, rodents). In 4-week subacute toxicity studies in rodents, no significant organ toxicity observed. Clinical trial data (3 g/day for 3 weeks) showed no significant adverse effects.

Special precautions

Pregnancy

Insufficient clinical data. Avoid during pregnancy based on lack of safety evidence.

Lactation

No data available on excretion in human breast milk. Avoid during breastfeeding.

Hepatic impairment

No hepatotoxicity reported in literature. Limited specific data; standard monitoring recommended.

Renal impairment

Preclinical evidence suggests renoprotective potential. No dose adjustment guidelines available; monitor renal function with regular use.

Sources and references

  1. [1] - Ontawong A., "A randomized controlled clinical trial examining the effects of Cordyceps militaris beverage on the immune response in healthy adults.", Sci Rep, 2024, PMID: 38580687
  2. [2] - Tsai YS., "Safety Assessment of HEA-Enriched Cordyceps cicadae Mycelium: A Randomized Clinical Trial.", J Am Coll Nutr, 2021, PMID: 32702252
  3. [3] - Yang EJ., "An Immunomodulatory Mushroom, Cordyceps militaris, and Its Constituents: A Review of In Vitro/In Vivo Studies and Clinical Trials.", Phytother Res, 2026, PMID: 41432716
  4. [4] - Das G., "Cordyceps spp.: A Review on Its Immune-Stimulatory and Other Biological Potentials.", Front Pharmacol, 2020, PMID: 33628175
  5. [5] - Łysakowska P., "Medicinal Mushrooms: Their Bioactive Components, Nutritional Value and Application in Functional Food Production-A Review.", Molecules, 2023, PMID: 37513265

Additional source links

Continue browsing